Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8,613,503 | $6,867,049 | $4,976,950 | $4,252,803 |
| - Cash | $306,948 | $147,767 | $148,615 | $92,365 |
| + Debt | $16,981 | $16,938 | $20,041 | $25,407 |
| Enterprise Value | $8,323,536 | $6,736,220 | $4,848,376 | $4,185,844 |
| Revenue | $680,852 | $464,370 | $249,132 | $81,708 |
| % Growth | 46.6% | 86.4% | 204.9% | – |
| Gross Profit | $623,889 | $430,625 | $228,689 | $73,673 |
| % Margin | 91.6% | 92.7% | 91.8% | 90.2% |
| EBITDA | -$116,721 | -$158,853 | -$262,970 | -$285,155 |
| % Margin | -17.1% | -34.2% | -105.6% | -349% |
| Net Income | -$74,676 | -$139,674 | -$256,256 | -$284,126 |
| % Margin | -11% | -30.1% | -102.9% | -347.7% |
| EPS Diluted | -0.72 | -1.46 | -2.72 | -3.5 |
| % Growth | 50.7% | 46.3% | 22.3% | – |
| Operating Cash Flow | -$73,177 | -$124,199 | -$270,186 | -$259,543 |
| Capital Expenditures | -$322 | -$269 | -$778 | -$326 |
| Free Cash Flow | -$73,499 | -$124,468 | -$270,964 | -$259,869 |